Table 1 Risk stratification of patients with SMM according to Mayo Clinic and Spanish models [12, 13]
From: Prognostic and predictive biomarker developments in multiple myeloma
| Â | Risk factors | 15-year progression (%) |
|---|---|---|
Mayo Clinic model | Group 1: M protein ≥ 30 g/L +  ≥ 10% BM plasma cells Group 2: M protein < 30 g/L +  ≥ 10% BM plasma cells Group 3: M protein ≥ 30 g/L +  < 10% BM plasma cells | Group 1: 87 Group 2: 70 Group 3: 39 |
| Â | Risk factors | 5-year PFS (%) |
|---|---|---|
Spanish model |  ≥ 95% abnormal plasma cells Immunoparaesis | Zero risk factors: 72 One risk factor: 46 Two risk factors: 4 |